Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AZD5991

Small molecule · Inhibitor of Mcl-1 (BCL2L1)

Phase 2/3 Most advanced trial
1 Registered trials

What is AZD5991?

AZD5991 is a small-molecule inhibitor of Mcl-1, an anti-apoptotic protein of the Bcl-2 family. By binding Mcl-1, it prevents inactivation of pro-apoptotic proteins and promotes apoptosis in cells overexpressing Mcl-1. It is studied in relapsed or refractory acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Mcl-1 (BCL2L1)
Mechanism
Inhibitor of Mcl-1 (BCL2L1)
Pathways
apoptosis
Therapy area
Hematology, Oncology
In trials of
SNDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
E3T5XXY9HX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03013998 Phase 2/3 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Recruiting SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on BCL2L1

Pelcitoclax Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.